Summary & Overview
HCPCS Level II J9144: Daratumumab 10 mg with Hyaluronidase, Subcutaneous Injection
HCPCS Level II code J9144 represents the subcutaneous combination product of daratumumab with hyaluronidase‑fihj, an oncology therapeutic used primarily in hematology/oncology care. Nationally, this code matters because it differentiates the subcutaneous formulation from intravenous alternatives, which can affect administration workflows, infusion suite time, and billing specificity across outpatient settings. Primary payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare.
Readers will learn what the code covers clinically and operationally, how it relates to other daratumumab codes, and what to expect in payer coverage considerations for outpatient oncology services. The publication provides concise benchmarks for coding and billing practice, notes common clinical contexts where the product is used in multiple myeloma and related plasma cell disorders, and identifies areas where policy language or coding guidance typically applies. Any missing service-line details are noted as "Data not available in the input." The content is intended for healthcare billing managers, oncology practice administrators, and clinical coders seeking a clear, nationally relevant summary of HCPCS Level II code J9144 and its role in outpatient oncology billing.
Billing Code Overview
HCPCS Level II code J9144 describes an injection of daratumumab, 10 mg combined with hyaluronidase‑fihj. This code is used for administration of the subcutaneous formulation of daratumumab with hyaluronidase as part of medical oncology and hematology treatment regimens.
Service type: Medical oncology / Hematology
Typical site of service: Outpatient (e.g., Physician Office or Hospital Outpatient)
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 67-year-old patient with relapsed multiple myeloma presents to an outpatient oncology infusion center for administration of daratumumab with hyaluronidase. The patient has a recent oncology visit documenting progressive disease after prior therapy and an order for subcutaneous daratumumab with hyaluronidase. Nursing triage confirms premedication given per protocol, verifies vitals and allergy history, performs site selection, and prepares the HCPCS Level II code J9144 dose-specified syringes. The medication is administered in the physician office or hospital outpatient infusion suite, observation for infusion‑related reactions is performed, and the encounter, drug amount administered, and any discarded drug are documented in the medication administration record and the claim.
Coding Specifications
-
HCPCS Level II code:
J9144— Injection, daratumumab, 10 mg and hyaluronidase‑fihj. -
Common modifiers:
-
JW- Drug amount discarded/not administered to any patient. Use when a portion of the prepared biologic is discarded and documentation supports the discarded amount. -
59- Distinct Procedural Service. Use when a service or procedure that is not normally reported together is distinct because it was performed at a separate session or an identifiable separate procedure; documentation must support the distinct service. -
Associated provider taxonomies:
| Taxonomy Code | Specialty |
|---|---|
207RH0003X | Hematology & Oncology Physician |
207RX0202X | Medical Oncology Physician |
208D00000X | General Practice Physician |
-
Notes on use:
-
Billing must identify the HCPCS Level II code
J9144and append appropriate modifier when applicable. Documentation must support modifierJWfor discarded drug and modifier59for distinct procedural services.
Related Diagnoses
-
C90.00- Multiple myeloma not having achieved remission- Clinical relevance: Indicates active multiple myeloma requiring systemic therapy such as daratumumab formulations.
-
C90.02- Multiple myeloma in relapse- Clinical relevance: Specifies relapsed disease where daratumumab may be indicated as part of salvage or subsequent lines of therapy.
-
C90.10- Plasma cell leukemia not having achieved remission- Clinical relevance: Denotes aggressive plasma cell neoplasm with active disease where anti‑CD38 therapies can be considered.
-
C90.12- Plasma cell leukemia in relapse- Clinical relevance: Reflects relapsed plasma cell leukemia needing further systemic treatment.
-
D47.Z9- Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue- Clinical relevance: Represents other hematologic neoplasms of uncertain behavior where clinical context may prompt use of hematology/oncology therapeutic agents.
-
If the ICD-10 list were empty: Data not available in the input.
Related Codes
-
J9145- Injection, daratumumab, 10 mg. -
Relationship to
J9144: -
J9145represents the same active agent without the hyaluronidase component; it is a related HCPCS Level II drug line item that may appear in claims when the formulation differs. -
Common use in workflow:
-
J9145is used as an alternative billing line when the non‑hyaluronidase formulation is administered.J9144andJ9145are not typically billed together for the same administration; one code is selected to match the administered formulation. -
If related codes list were empty: Data not available in the input.
National Reimbursement Benchmarks
National mean allowed rates for HCPCS Level II code J9144 show a wide gap between Medicare and average commercial (BUCA): BUCA’s mean is $184.34 compared with Medicare, which is not provided in the input (Medicare mean rate data not available in the input). Aetna’s mean rate is an outlier at $543.97 among commercial payers.
Rate dispersion measured by the interquartile spread (P75 minus P25) is narrowest for Cigna Health (56.00 - 56.00 = 0.00) and relatively tight for Blue Cross Blue Shield (60.00 - 55.00 = 5.00). The widest dispersion among provided payers is for Aetna (57.00 - 34.50 = 22.50). The table and chart below present the full breakdown.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.